Antidiabetic Biosimilars Market Enhancement in Medical Sector 2017 to 2022
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to patients as the reference product.
Patent expiries to drive growth of the global antidiabetic biosimilars market
The global antidiabetic biosimilars market is driven by increasing number of diabetes mellitus patients. According to World Health Organization (WHO) the number of people suffering from diabetes stood at 422 million in 2014. The global prevalence of diabetes among adults above 18 years increased to 8.5% in 2014 from 4.7% in 1980. Increasing incidence of lifestyle disorders such as obesity, increases the risk of diabetes and in turn drives growth of the antidiabetic biosimilars market. In June 2014, the European Medicines Agency authorized the first biosimilar of insulin Glargine, Abasaglar from Eli Lilly and Company and Boehringer Ingelhim International Gmbh, for treatment of diabetes mellitus. The biosimilar received U.S. FDA approval in 2016, which would fuel growth of the antidiabetic biosimilars market.
Get The Holistic SAMPLE With Research Methodology:
Constraints for growth of the antidiabetic biosimilars market
Biosimilars would have to face stringent regulatory requirements that would focus on their production before entering into major markets such as the U.S. While biosimilars have marked successful entry in the European markets, entry in the U.S. market is still a challenge due to stringent regulatory norms. Furthermore, biosimilars would need to gain favorable reimbursement to gain market traction.
Increasing number of diabetes patients driving the antidiabetic biosimilars market globally
Increasing incidence of diabetes, complexities in alternative diabetic therapies, and government incentives for introduction of low cost therapies are collectively creating a conducive environment for growth of the market. According to the International Diabetes Federation (IDF), there were around 59.8 million diabetic patients in Europe in 2015. The market for antidiabetic biosimilar is expected to be high in near future in Asia Pacific due to increase in research activities related to antidiabetic products and supportive government funding. North America region is projected to represent a lucrative market for antidiabetic biosimilar in the near future, as prevalence of diabetes is increasing in this region. According to the International Diabetes Federation, in 2015, over 29.1 million people in the U.S. suffered from diabetes.
Get Table Of Content:
You may be interested
Researchers Identify Mechanism behind Brain’s Ability to Distinguish SmellsMohit Joshi - December 14, 2018
Researchers from Salk Institute identify the mechanism of neurons in brain's piriform cortex that allows to differentiate one smell from another. The piriform cortex situated in the…
Gasoline Type Portable Generator Market 2018 – 2023 Trends, Analysis, Market Forecast, Production DemandAlbert R - December 13, 2018
Gasoline Type Portable Generator Market is anticipated to have maximum growth during years 2018 to 2023 according to the latest research made by WMR. This Gasoline Type…
2018 – 2023 Hydroponic Equipments Market Report | Top Competitors, Features, Application And RegionsAlbert R - December 13, 2018
Hydroponic Equipments Market is anticipated to have maximum growth during years 2018 to 2023 according to the latest research made by WMR. This Hydroponic Equipments Market Intelligence…